LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

Nanshan Zhong,1 Changzheng Wang,2 Xiangdong Zhou,3 Nuofu Zhang,1 Michael Humphries,4 Linda Wang,4 Chau Thach,5 Francesco Patalano,6 Donald Banerji5On behalf of the LANTERN Investigators 1State Key Laboratory of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou,...

Full description

Bibliographic Details
Main Authors:	Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-06-01
Series:	International Journal of COPD
Online Access:	http://www.dovepress.com/lantern-a-randomized-study-of-qva149-versus-salmeterolfluticasone-comb-peer-reviewed-article-COPD

Similar Items

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
by: Vogelmeier C, et al.
Published: (2016-12-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
by: Wedzicha JA, et al.
Published: (2017-01-01)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
by: Horita N, et al.
Published: (2015-04-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
by: Antonio R. Anzueto, et al.
Published: (2018-06-01)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
by: Anzueto AR, et al.
Published: (2017-05-01)

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD
by: Martyn R. Partridge, et al.
Published: (2009-08-01)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
by: Barbara P Yawn, et al.
Published: (2010-06-01)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
by: Beatrix Balint, et al.
Published: (2010-09-01)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study
by: Dahl R, et al.
Published: (2013-10-01)

Cost-effectiveness of combination fluticasone propionate&ndash;salmeterol 250/50 &mu;g versus salmeterol in severe COPD patients
by: An, et al.
Published: (2010-06-01)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
by: Dahl R, et al.
Published: (2014-01-01)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
by: Henrik Watz, et al.
Published: (2020-05-01)

Effects of Salmeterol and Fluticasone Propionate Combination versus Fluticasone Propionate on Airway Function and Eosinophilic Inflammation in Mild Asthma
by: Makoto Hoshino, et al.
Published: (2009-01-01)

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
by: Gao J, et al.
Published: (2015-04-01)

Effect of combined application of tiotropium and Salmeterol and fluticasone propionate powder on disease control in stable COPD patients
by: Xiu-Ping Han, et al.
Published: (2016-06-01)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
by: Xiaofen Jin, et al.
Published: (2020-01-01)

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
by: Jadwiga A. Wedzicha, et al.
Published: (2019-01-01)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
by: Moretz C, et al.
Published: (2020-10-01)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01)

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
by: Leif Bjermer, et al.
Published: (2017-12-01)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
by: Yoxall Sally, et al.
Published: (2007-07-01)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
by: Woodcock Ashley, et al.
Published: (2007-09-01)

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization
by: Nina Maria Ainali, et al.
Published: (2020-08-01)

Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone
by: Mario Cazzola, et al.
Published: (2009-04-01)

Efficacy of indacaterol 75 &micro;g versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
by: Cope S, et al.
Published: (2012-07-01)

Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma
by: Michela Bullone, et al.
Published: (2017-08-01)

Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone
by: Robyn Teply, et al.
Published: (2010-03-01)

Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma
by: Stanford RH, et al.
Published: (2012-12-01)

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
by: Moretz C, et al.
Published: (2019-08-01)

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device
by: Donald P. Tashkin, et al.
Published: (2021-01-01)

Effect of tiotropium bromide combined with salmeterol fluticasone inhalation on airway function and airway inflammation in patients with moderate-severe stable COPD
by: Min Xiang
Published: (2016-12-01)

Effect of salmeterol/fluticasone combination on the dynamic changes of lung mechanics in mechanically ventilated COPD patients: a prospective pilot study
by: Chen WC, et al.
Published: (2016-01-01)

Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
by: Dalal AA, et al.
Published: (2012-01-01)

Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
by: David M.G. Halpin, et al.
Published: (2021-02-01)

The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study
by: Jones R, et al.
Published: (2017-08-01)

A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler in routine clinical practice
by: Ines Vinge, et al.
Published: (2021-08-01)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
by: Perrone V, et al.
Published: (2016-11-01)

Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study
by: McAulay Kirsten, et al.
Published: (2011-05-01)

Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach
by: Lakhotia B, et al.
Published: (2020-04-01)

Treatment adherence and level of control in moderate persistent asthma in children and adolescents treated with fluticasone and salmeterol
by: Nulma S. Jentzsch, et al.
Published: (2019-01-01)